Background/Aims: The purpose of this study was to examine whether tacrolimus is effective and safe, and to determine the optimal dose of tacrolimus for maintenance treatment in patients with lupus nephritis (LN). Methods: A total of 17 adult patients (1 man and 16 women) with LN were enrolled. Tacrolimus was initiated at a dose of 3 mg/day which was administered once per day after the evening meal. Prospective data on renal response and serologic lupus activity were collected and followed for a year. Results: Mean age at baseline was 48.8 ± 12.6 years (range 31–72 years). The mean urinary protein/creatinine ratio significantly decreased from 1.14 ± 1.74 at baseline to 0.23 ± 0.47 at 1 year (p < 0.05). Mean serum C3 significantly increased from 73.0 ± 12.3 mg/dl at baseline to 84.7 ± 12.2 mg/dl at 1 year (p < 0.01). Mean serum creatinine levels were unchanged after tacrolimus treatment. The mean blood concentration of tacrolimus was 3.9 ± 2.1 ng/ml. There was no relationship between the incidence of adverse effects and blood tacrolimus level. Conclusion: Our results suggest tacrolimus to be potentially effective and safe for maintenance treatment in patients with LN.

Keywords:
Tacrolimus, Lupus nephritis, Proteinuria, Complement
1.
Bernatsky S, Boivin JF, Joseph L, et al: Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–2557.
2.
Pollak VE, Pirani CL, Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964;63:537–550.
3.
Austin HA 3rd, Klippel JH, Balow JE, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614–619.
4.
Boumpas DT, Austin HA 3rd, Vaughn EM, et al: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741–745.
5.
Gourley MF, Austin HA 3rd, Scott D, et al: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549–557.
6.
Illei GG, Austin HA, Crane M, et al: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248–257.
7.
Hallegua D, Wallace DJ, Metzger AL, et al: Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000;9:241–251.
8.
Radhakrishnan J, Kunis CL, D’Agati V, et al: Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147–154.
9.
Chan TM, Li FK, Tang CS, et al: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156–1162.
10.
Chan TM, Tse KC, Tang CS, et al: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076–1084.
11.
Cross J, Dwomoa A, Andrews P, et al: Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005;100:c92–c100.
12.
Aihara Y, Miyamae T, Ito S, et al: Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr Int 2002;44:199–204.
13.
Tanaka H, Oki E, Tsuruga K, et al: Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract 2008;110:c73–c79.
14.
Kobert SM, Lewis EJ, Schwartz MM, et al: Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904–914.
15.
Mok CC, Tong KH, To CH, et al: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005;68:813–817.
16.
Politt D, Heintz B, Floege J, et al: Tacrolimus (FK506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 2004;62:49–53.
17.
Tse KC, Lam MF, Tang SCW, et al: A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibitor or blockade. Lupus 2007;16:46–51.
18.
Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–1277.
19.
Weening JJ, D’Agati VD, Schwartz MM, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241–250.
20.
Suzuki K, Kameda H, Amano K, et al: Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int 2009;29:431–436.
21.
Tamura K, Kobayashi M, Hashimoto K, et al: A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc 1987;19:23–29.
22.
Taylor PJ, Morris RG: Tacrolimus measurement by microparticle enzyme immunoassay. Ther Drug Monit 2003;25:259–260.
23.
Moroni G, Quaglini S, Maccario M, et al. ‘Nephritic flares’ are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047–2053.
24.
Aran AA, Putterman C: Treatment of lupus nephritis: facing the era of immunotherapy. Panminerva Med 2008;50:235–245.
25.
Ranchin B, Fargue S: New treatment strategies for proliferative lupus nephritis: keep children in mind! Lupus 2007;16:684–691.
26.
Duddridge M, Powell RJ: Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997;56:690–692.
27.
Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004;78:557–565.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.